A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice

Two recently approved PARP inhibitors provide an important new therapeutic option for patients with BRCA-mutated metastatic breast cancer. PARP inhibitors significantly prolong progression-free survival in patients, but conventional oral delivery of PARP inhibitors is hindered by limited bioavailability and off-target toxicities, thus compromising the therapeutic benefits and quality of life for patients. Here, we developed a new delivery system, in which the PARP inhibitor Talazoparib is encapsulated in the bilayer of a nano-liposome, to overcome these limitations. Methods: Nano-Talazoparib (NanoTLZ) was characterized both in vitro and in vivo. The therapeutic efficacy and toxicity of Nano-Talazoparib (NanoTLZ) were evaluated in BRCA-deficient mice. The regulation of NanoTLZ on gene transcription and immunomodulation were further investigated in spontaneous BRCA-deficient tumors. Results: NanoTLZ significantly (p<0.05) prolonged the overall survival of BRCA-deficient mice compared to all of the other experimental groups, including saline control, empty nanoparticles, and free Talazoparib groups (oral and i.v.). Moreover, NanoTLZ was better tolerated than treatment with free Talazoparib, with no significant weight lost or alopecia as was observed with the free drug. After 5 doses, NanoTLZ altered the expression of over 140 genes and induced DNA damage, cell cycle arrest and inhibition of cell proliferation in the tumor. In addition, NanoTLZ favorably modulated immune cell populations in vivo and significantly (p<0.05) decreased the percentage of myeloid derived suppressor cells in both the tumor and spleen compared to control groups. Conclusions: Our results demonstrate that delivering nanoformulated Talazoparib not only enhances treatment efficacy but also reduces off-target toxicities in BRCA-deficient mice; the same potential is predicted for patients with BRCA-deficient breast cancer.

[1]  D. Dinulescu,et al.  Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model , 2019, Front. Oncol..

[2]  E. Andrechek,et al.  Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice. , 2018, Antioxidants & redox signaling.

[3]  B. Tunca,et al.  Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer , 2018, Pharmaceutical Research.

[4]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[5]  X. Guan,et al.  Emerging therapeutic modalities of PARP inhibitors in breast cancer. , 2018, Cancer treatment reviews.

[6]  A. Mills,et al.  Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer , 2018, Theranostics.

[7]  G. Mills,et al.  A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors , 2017, Clinical Cancer Research.

[8]  Anne L. van de Ven,et al.  Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer , 2017, Theranostics.

[9]  David C. Smith,et al.  Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. , 2017, Cancer discovery.

[10]  Anne L. van de Ven,et al.  Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation , 2017, Molecular Cancer Therapeutics.

[11]  G. Hortobagyi,et al.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.

[12]  Vladimir Torchilin,et al.  Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform , 2016, Molecular Cancer Therapeutics.

[13]  C. Turner,et al.  Myosin 1e promotes breast cancer malignancy by enhancing tumor cell proliferation and stimulating tumor cell de-differentiation , 2016, Oncotarget.

[14]  R. Kelley,et al.  Efficacy and hematologic toxicity of carboplatin and talazoparib combination therapy in BRCA mutated patients. , 2016 .

[15]  Wan-Xi Yang,et al.  Myosins as fundamental components during tumorigenesis: diverse and indispensable , 2016, Oncotarget.

[16]  B. Wang,et al.  Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. , 2016, Journal of medicinal chemistry.

[17]  M. McVey,et al.  Error‐Prone Repair of DNA Double‐Strand Breaks , 2016, Journal of cellular physiology.

[18]  Michael S. Goldberg,et al.  The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. , 2015, Biochemical and biophysical research communications.

[19]  P. Fracasso,et al.  A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. , 2015, Gynecologic oncology.

[20]  A. Molinari,et al.  Liposomes as nanomedical devices , 2015, International journal of nanomedicine.

[21]  S. Chin,et al.  BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells , 2015, Nature Communications.

[22]  G. Mufti,et al.  Applying synthetic lethality for the selective targeting of cancer. , 2014, The New England journal of medicine.

[23]  E. Winer,et al.  Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  L. Zhang,et al.  Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis , 2014, British Journal of Cancer.

[25]  Y. Pommier,et al.  Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib , 2013, Molecular Cancer Therapeutics.

[26]  J. Markowitz,et al.  Myeloid-derived suppressor cells in breast cancer , 2013, Breast Cancer Research and Treatment.

[27]  Mads Thomassen,et al.  Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling , 2013, PloS one.

[28]  D. Matei,et al.  First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors , 2013 .

[29]  M. Ranson,et al.  Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study , 2012, Investigational New Drugs.

[30]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[31]  G. Giaccone,et al.  A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors , 2012, Clinical Cancer Research.

[32]  G. Rockwood,et al.  Optimization of Liposomal Lipid Composition for a New, Reactive Sulfur Donor, and In Vivo Efficacy Studies on Mice to Antagonize Cyanide Intoxication , 2011, Journal of drug delivery.

[33]  M. Sporn,et al.  CDDO-Methyl Ester Delays Breast Cancer Development in Brca1-Mutated Mice , 2011, Cancer Prevention Research.

[34]  J. Larkin,et al.  A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours , 2011, British Journal of Cancer.

[35]  S. McColl,et al.  Multiple functions of CXCL12 in a syngeneic model of breast cancer , 2010, Molecular Cancer.

[36]  Yong Zhang,et al.  PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..

[37]  G. Feldman,et al.  Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2 , 2010, Genetics in Medicine.

[38]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[39]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[40]  J. Oosterwijk,et al.  Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age , 2010, Breast Cancer Research and Treatment.

[41]  V. Torchilin.  Targeted pharmaceutical nanocarriers for cancer therapy and imaging , 2007, The AAPS Journal.

[42]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[43]  C. Deng,et al.  BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution , 2006, Nucleic acids research.

[44]  Alan Ashworth,et al.  Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue , 2006, Modern Pathology.

[45]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[46]  R. Puri,et al.  Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor α2 chain in vivo , 2003, Gene Therapy.

[47]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[48]  C. Deng,et al.  Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice , 2001, Oncogene.

[49]  R. B. Campbell,et al.  Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. , 2001, Journal of pharmaceutical sciences.

[50]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[51]  D. Livingston,et al.  In search of the tumour-suppressor functions of BRCA1 and BRCA2 , 2000, Nature.

[52]  F. Couch,et al.  BRCA1 Facilitates Stress-induced Apoptosis in Breast and Ovarian Cancer Cell Lines* , 2000, The Journal of Biological Chemistry.

[53]  Thomas Ried,et al.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation , 1999, Nature Genetics.

[54]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[55]  K. Altundağ.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.

[56]  Jinming Gao,et al.  Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. , 2014, Critical reviews in eukaryotic gene expression.

[57]  L. Saal,et al.  Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair , 2008, Nature Genetics.

[58]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.